Get your weed from Trulieve? You can now buy its shares on the NYSE
The listing gives investors their first chance to buy shares of a U.S. cannabis company on the exchange, after a federal rescheduling change opened the door.
- On Wednesday, Florida-based Trulieve became the first U.S. cannabis company to list on the New York Stock Exchange under ticker TRLV, ending its prior trading on the Canadian Securities Exchange since 2018.
- The listing follows the Trump administration's April reclassification of medical marijuana from Schedule I to Schedule III, enabling Trulieve to restructure and split its medical and recreational operations.
- Story Cannabis CEO Jason Vedadi called the shift "pretty darn great," while Arizona Dispensaries Association executive director Ann Torrez described the uplisting as a "defining moment in the cannabis industry."
- Vedadi predicts the debut will bring "massive amounts" of money into the industry, as institutions and hedge funds now view cannabis as a viable investment opportunity.
- Ahead of upcoming federal rescheduling hearings beginning at month's end, competitors Curaleaf and Verano are preparing for potential uplisting as recreational cannabis rescheduling could simplify future listings.
14 Articles
14 Articles
Trulieve debuts on NYSE
Florida-based MSO Trulieve went public on the New York Stock Exchange in an important first for the licensed cannabis industry. The move follows the Trump administrations rescheduling of MED to a schedule III substance under the Controlled Substances Act and comes weeks before DEA hearings are set to begin on rescheduling REC. Trulieve CEO Kim Rivers has gained a reputation as the industry's "Trump whisperer." His unexpected decision to reschedu…
Trulieve Breaks Ground with NYSE Cannabis Listing
Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) has secured approval to list its subordinate voting shares on the New York Stock Exchange (NYSE), marking the first time a US plant-touching marijuana operator has gained access to a major domestic equity market.Major US exchanges have historically barred cannabis operators due to the drug's status as a Schedule I controlled substance. To clear the compliance hurdles required by the NYSE, Trulieve execute…
Trulieve’s NYSE listing is a ” landmark milestone”, this analyst says
Haywood Securities analyst Neal Gilmer says Trulieve Cannabis’ (Trulieve Cannabis Stock Quote, Chart, News, Analysts, Financials CSE:TRUL) approval to list on the New York Stock Exchange is a landmark event for the company and the broader U.S. cannabis sector. In a June 8 update, Gilmer raised his target on Trulieve to C$24.00 from C$19.00 and […] Source
Cannabis News Today — 10 Jun 2026: Trulieve Hits NYSE
Wednesday brings a landmark for cannabis capital markets, with Trulieve set to become the first US plant-touching operator to open trading on the New York Stock Exchange and Verano preparing its own exchange push via a reverse stock split. In Virginia, Governor Spanberger’s negotiations with legislators over adult-use sales are converging on a 1 July budget deadline. The EU Drugs Agency’s 2026 annual report, released in Brussels on Tuesday, plac…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
